CoChat
Sign Up
Cited by 33Cancer survivorship and careProstate Cancer Diagnosis and TreatmentCancer-related cognitive impairment studies

Pretreatment depressive symptoms and treatment modality predict post-treatment disease-specific quality of life among patients with localized prostate cancer

Open access
Mohamed, Nihal E., Bovbjerg, Dana H., Montgomery, Guy H., Hall, Simon J., Diefenbach, Michael A.·2012·Urologic Oncology: Seminars and Original Investigations
DOI 10.1016/j.urolonc.2011.02.002PMC PMC4112499
Open this paper in CoChat — free account

Abstract

Purpose This study examines the prevalence of depressive symptoms before prostate cancer treatment and explores associations among pre-treatment depressive symptoms and post-treatment disease-specific QOL, controlling for treatment modality, and demographic and clinical covariates.Materials and methods A case series of patients diagnosed with localized prostate cancer (T1-2N0M0) at a comprehensive cancer center was assessed. Of the 1,370 eligible patients, 869 (63.34%) completed questionnaires at diagnosis (baseline) and 6 months following treatment. Patients were treated with surgery (16.8%), brachytherapy (27.6%), or external beam radiation (EBRT; 55.6%). Depressive symptoms and disease-specific QOL were assessed with established measures (i.e., Center for Epidemiologic Studies Depression Scale (CES-D); sexual adjustment questionnaire (SAQ); and the American Urological Association symptom index).Results A fifth of the sample (19.7%) reported clinically elevated levels of depressive symptoms at baseline. The proportion of clinically elevated levels of baseline depressive symptoms was higher among surgery patients compared with patients treated with brachytherapy or external beam radiation. Depressive symptoms at baseline and treatment modality significantly predicted sexual and urinary dysfunction, related bother, activity limitation due to urinary dysfunction at 6 months, controlling for, age, PSA level, Gleason score, relevant baseline indicators of sexual and urinary dysfunction, related bother, and activity limitation (P < 0.05).Conclusions Pretreatment depressive symptoms and treatment modality predict QOL after PrCa treatment. Health care providers should be sensitive to the display of depressive symptoms before PrCa treatment and consider preventative interventions, including preparing patients for the changes in disease-specific QOL and related bother following prostate cancer treatment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.urolonc.2011.02.002

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Previous studies have reported negative side effects of fatigue, sleep disturbance, anxiety and depression among men diagnosed with PC during and following RT.

    “Previous studies have reported the negative side effects of fatigue, sleep disturbance, anxiety and depression among men diagnosed with PC during and following RT.3,8-11”

    From Implementation Readiness and Initial Effects of a Brief Mindfulness Audio Intervention Compared With a Brief Music Control During Daily Radiation Therapy for Prostate Cancer: A Randomized Pilot Study. (2024) · cites this paper as [11]

    The Introduction reports depression and psychological distress after prostate cancer diagnosis and notes that depressive symptoms may persist after treatment. The Results include patients treated with external-beam radiation, but the paper does not report fatigue, sleep disturbance, or anxiety as effects during or following radiation therapy, nor establish that depression is a side effect of that treatment. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. [4]Massie MJ Popkin MK Holland JC Depressive disorders Psychooncology 1998 New York Oxford University Press 518 540
  2. [26]Cliff AM Macdonagh RP Psychosocial morbidity in prostate cancer: II. A comparison of patients and partners BJUI 68 834 883 11069410

Cited by

Sorted by citations

Related

Authors
Mohamed, N. E., Bovbjerg, D. H., Montgomery, G. H., Hall, S. J., & Diefenbach, M. A.
Affiliations
  • Icahn School of Medicine at Mount Sinai (US)
  • University of Pittsburgh (US)
  • Mount Sinai Hospital (US)
Corresponding author
Mohamed, Nihal E.
ORCID
Venue
Urologic Oncology: Seminars and Original Investigations
Publisher
Elsevier BV
Published
2012-11
Volume
30
Issue
6
Pages
804-812
ISSN
1078-1439 (ISSN-L)
DOI
10.1016/j.urolonc.2011.02.002
PMC
PMC4112499
OpenAlex
W2045976162
Cited by
33
References
52
Citations by year
2024: 3 · 2022: 3 · 2021: 2 · 2020: 1 · 2019: 5 · 2018: 3 · 2017: 4 · 2016: 2 · 2015: 2 · 2014: 2 · 2013: 4 · 2012: 2
FWCI
1.26
Type
journal article
Language
en
Open access
Licence
Locations
  • Urologic Oncology Seminars and Original Investigations (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • U.S. Department of Defense (DAMD 17-1-1-006)
  • National Cancer Institute (R25CA129094, CA6136-04)
Topics
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
Keywords
localized prostate cancer, depressive symptoms, disease-specific quality of life, treatment options, brachytherapy, external beam radiotherapy, prostatectomy, sexual dysfunction, urinary dysfunction, activity limitation
MeSH terms
Aged, Depression, Humans, Male, Middle Aged, Prostatic Neoplasms, Quality of Life, Surveys and Questionnaires, Prevalence, Prostate-Specific Antigen, Neoplasm Grading

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review